A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic LymphomaXiao‐Peng Tian, Guo‐Wei Li, Ning Su et al.|Clinical Cancer Research|2020Cited by 40
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)Yuankai Shi, Lin Wang, Jianhua Chen et al.|Journal of Thoracic Oncology|2024Cited by 40
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)Yuankai Shi, Xiaoyan Kang, Jianhua Chen et al.|BMC Medicine|2023Cited by 24
Supplementary Figure S12 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic LymphomaXiao-Peng Tian, Guo‐Wei Li, Ning Su et al.|Unknown|2023Cited by 0
Supplementary Figure S2 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic LymphomaXiao-Peng Tian, Guo‐Wei Li, Ning Su et al.|Unknown|2023Cited by 0